EDISON EQUITY RESEARCH: RXI PHARMACEUTICALS
November 16 2015 - 5:10PM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH:
RXI PHARMACEUTICALS - DELIVERING ON ITS SELF-DELIVERING RNAI
PLATFORM
Over the past year, RXi
Pharmaceuticals (RXi) has made significant headway with its
pipeline as well as in securing partnerships. Its lead compound
RXI-109 is in Phase II in dermatological scarring and is entering
the clinic this year in retinal scarring in wet AMD. Phase II
dermatology treatment Samcyprone was in-licensed, while a deal was
struck with MirImmune for the out-licensing of its proprietary
sd-rxRNA technology. We expect the company’s budding pipeline,
recently simplified shareholder structure and deal-oriented
strategy will continue to garner renewed investor attention and
share price momentum. We value RXi at $91m or $1.40 per
share.
RXi is an early-stage drug
development company focused primarily on dermatology and
ophthalmology. Lead clinical projects, RXI-109 in dermal
indications (Phase II) and in AMD (Phase I ready) stem from its
proprietary self-delivering sd-rxRNA platform. Licensed-in
immunomodulator Samcyprone is initially being developed for warts,
alopecia areata and melanoma.
To view our full report,
please click here
Click here to view all of Edison Investment
Research’s published reports
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Mar 2024 to Apr 2024
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Apr 2023 to Apr 2024